Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Immunocore Holdings (IMCR) over the last 3 years, with Q3 2025 value amounting to -$287000.0.

  • Immunocore Holdings' Change in Account Payables rose 6301.55% to -$287000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 6091.78%. This contributed to the annual value of $7.3 million for FY2024, which is 17702.86% up from last year.
  • As of Q3 2025, Immunocore Holdings' Change in Account Payables stood at -$287000.0, which was up 6301.55% from -$6.9 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Change in Account Payables ranged from a high of $6.0 million in Q2 2023 and a low of -$6.9 million during Q2 2025
  • Its 3-year average for Change in Account Payables is $547545.5, with a median of -$287000.0 in 2025.
  • Examining YoY changes over the last 5 years, Immunocore Holdings' Change in Account Payables showed a top increase of 24405.17% in 2025 and a maximum decrease of 25452.72% in 2025.
  • Immunocore Holdings' Change in Account Payables (Quarter) stood at $3.8 million in 2023, then surged by 56.7% to $5.9 million in 2024, then plummeted by 104.88% to -$287000.0 in 2025.
  • Its Change in Account Payables stands at -$287000.0 for Q3 2025, versus -$6.9 million for Q2 2025 and $3.3 million for Q1 2025.